It is expected that blockbuster vaccine varieties will resume sales growth trend in 2025 under a low base
May 26, 2025
Source: drugdu
77
Xinhua Finance Beijing May 22nd CITIC Construction InvestmentThe research report pointed out that the overall number of vaccine batches issued in the first quarter of 2025 was 697, a year-on-year decrease of 14% .Vaccines, diphtheria, pertussis and hepatitis vaccines increased significantly year-on-year, while polio vaccines, herpes zoster vaccines, rotavirus vaccines and HPV vaccines decreased significantly year-on-year. In terms of research and development, tumor therapeutic vaccines have become a hot area for the expansion of vaccine indications, and domestic research and development is in its infancy; while there are many domestic companies with traditional blockbuster vaccine pipelines, and the competition landscape is becoming fierce. It is expected that in 2025, blockbuster vaccine varieties will resume sales growth on a low base, driving corporate performance improvements. The continuous advancement of innovative vaccine pipelines will bring companies greater market space and potential overseas opportunities in the future.
https://finance.eastmoney.com/a/202505223411350774.html
Copyright©2025 Ddu. All rights reserved.
Read more on
- Bedaquiline Fumarate API Approved for Marketing, Enriching Anti-TB Drug Product Line July 25, 2025
- Huadong Medicine’s subsidiary’s Caspofungin Acetate for Injection approved by the U.S. FDA July 25, 2025
- Good news from AstraZeneca July 25, 2025
- A breakthrough in the cure of hepatitis B is in sight, and the share prices of leading pharmaceutical companies have doubled July 25, 2025
- A new hotspot in the innovative drug market July 25, 2025
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
